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Words can do a lot of harm. One wrong headline in the lay 
press, shared on social media, can lead to a lot of misery. 
Misery for the women who underwent preventive breast 
surgery in the past and now could read in the news that this 
drastic operation may have been unnecessary. Misery for all 
dedicated clinicians who had to reassure these women that 
they had made the right decision, and also frustration for all 
investigators involved in the original paper who saw their 
message being framed so wrongly.
We recently reported lower overall and breast cancer-spe-
cific mortality rates among BRCA1 mutation carriers opting 
for bilateral risk-reducing mastectomy (BRRM) than among 
those under surveillance. For BRCA2 mutation carriers, 
BRRM was non-significantly associated with lower overall 
mortality when compared with surveillance. Additionally, 
we observed more favorable characteristics of BRCA2-asso-
ciated breast tumors, which eventually may lead to compara-
ble breast cancer-specific mortality rates after either BRRM 
or surveillance. We concluded that our findings may support 
a more individualized counseling, based on BRCA muta-
tion type, regarding the difficult choice between BRRM and 
breast cancer surveillance [1].
We certainly did not conclude that women carrying 
a BRCA2 mutation should be informed that BRRM is an 
over-treatment, as was presumed by Neven et al. [2]. Indeed, 
to our great dismay the results of our study have been dis-
torted in the Dutch newspaper Algemeen Dagblad edition 
29/07/2019 with the headline “Preventive breast surgery 
appears not to be necessary”, as already noted by Evans 
et al. [3].
We understand and share the concern of our colleagues 
from Leuven and Manchester that our message was framed 
so wrongly in the lay press and thus has upset many women 
and their physicians. Immediately after the appearance of 
the news article, we and colleagues from several medical 
centers and from patient advocate groups have been busy in 
all kinds of media—radio, television, newspapers, websites 
for BRCA mutation carriers—to unnerve the headline and 
reassure women that their decision to opt for BRRM to pre-
vent breast cancer was a right decision—as is the decision of 
other women to remain under intensive surveillance.
In the current counseling process, BRRM and surveil-
lance are discussed as two reasonable options for healthy 
BRCA1/2 mutation carriers. The wish to avoid a breast can-
cer diagnosis and resultant treatment and the anxiety related 
to the frequent and ongoing surveillance—with unchanged 
high breast cancer risks—are recognized as the main reasons 
for women to decide for BRRM. Thus far, mortality rates 
have had no significant impact on the decision process—
probably also because reliable figures were lacking. In this 
study, we showed that for BRCA1 mutation carriers’ life 
expectancy is somewhat higher after BRRM. In our opin-
ion, this finding may be relevant in the difficult individual 
decision-making process between both options.
On behalf of all co-authors,
B.A.M. Heemskerk-Gerritsen and M.J. Hooning
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